

What is claimed is:

1. A composition comprising:

5 (a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and

(b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof.

10

2. The composition according to claim 1 wherein component (a) is selected from the group consisting of tandamine, pirandamine, ciclazindol, fluparoxan, lortalamine, talsupram, talopram, prindamine, nomifensine, viloxazine, tomoxetine, duloxetine, venlafaxine, milnacipran and reboxetine and mixtures thereof.

15

3. The composition according to claim 2 wherein component (a) is reboxetine in either its racemic or +(S,S) enantiomeric form.

20

4. The composition according to claim 3 containing between about 0.1 mg to about 10 mg reboxetine.

25

5. The composition according to claim 1 wherein component (b) is selected from the group consisting of chlorpromazine, haloperidol, perphenazine, thioridazine, mesoridazine, trifluoperazine, fluphenazine, clozapine, olanzapine, risperidone, ziprasidone, quetiapine, sertindole, aripiprazole, sonopiprazole, blonanserin, iloperidone, perospirone, raclopride, zotepine, DU-127090, ORG-5222, SM-13496, amisulpride, CP-361428, Lu 35-138, balaperidone, S-18327, WAY-135452, eplivanserin, E-5842, SR-31742, NE-100, osanetant, SR-141716, SR-48692, BSF-201640, BSF-190555, LAX-101a, sarizotan, CX-691 and SB-271046 and mixtures thereof.

30

6. The composition according to claim 5 wherein component (b) is selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof.

7. The composition according to claim 1 wherein component (a) and component (b) are maintained in the same delivery vehicle.

5 8. The composition according to claim 1 wherein component (a) and component (b) are maintained in different delivery vehicles.

9. A method for treating a disease or disorder of the central nervous system in a mammal comprising administering to said mammal a pharmaceutically effective amount of a composition comprising:

10

(a) a pharmaceutically effective amount of one or more selective norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and

15 (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof.

10. The method according to claim 9 wherein said disease or disorder is selected from the group consisting of obesity, depression, schizophrenia, a stress related disease, panic disorder, a phobia, obsessive compulsive disorder, post-traumatic-stress syndrome, immune system depression, a stress induced problem with the urinary, gastrointestinal or cardiovascular system, neurodegenerative disorders, autism, chemotherapy-induced vomiting, hypertension, migraine headaches, cluster headaches, incontinence, sexual dysfunction, addictive disorder and withdrawal syndrome, an adjustment disorder, an age-associated learning and mental disorder, anorexia nervosa, apathy, an attention-deficit disorder due to general medical conditions, attention-deficit hyperactivity disorder, bipolar disorder, bulimia nervosa, chronic fatigue syndrome, conduct disorder, cyclothymic disorder, dysthymic disorder, fibromyalgia and other somatoform disorders, generalized anxiety disorder, an inhalation disorder, an intoxication disorder, a movement disorder, oppositional defiant disorder, a pain disorder, peripheral neuropathy, post-traumatic stress disorder, premenstrual dysphoric disorder, a psychotic disorder, seasonal affective disorder, a

20

25

30

sleep disorder, a specific developmental disorder, and selective serotonin reuptake inhibition (SSRI) "poop out" syndrome.

11. The method of claim 9 wherein said composition is administered rectally,
5 topically, orally, sublingually, intranasally, transdermally or parenterally.

12. The method according to claim 9 wherein component (a) and component (b) of said composition are simultaneously administered.

10 13. The method according to claim 9 wherein component (a) and component (b) of said composition are concomitantly administered.

14. The method according to claim 9 wherein said disease or disorder comprises schizophrenia.

15 15. The method according to claim 9 wherein component (a) of said composition comprises reboxetine in its racemic or enantiomeric form.

16. The method according to claim 15 wherein between about 0.1 mg to about 10
20 mg reboxetine is administered to the patient on a daily basis.

17. The method according to claim 9 wherein said neuroleptic agent is selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof.

25 18. A composition consisting essentially of:

(a) a pharmaceutically effective amount of reboxetine in its racemic or enantiomeric form; and

30 (b) a pharmaceutically effective amount of one or more neuroleptic agents selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof or a pharmaceutically effective salt thereof;

wherein components (a) and (b) are maintained in the same or in different delivery vehicles.

5 19. The use of a composition comprising:

(a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and

10 (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof to prepare a medicament for treating or preventing diseases or disorders of the central nervous system.

15 20. The use according to claim 19 wherein component (a) comprises reboxetine in its racemic or enantiomeric form.

21. The use according to claim 19 wherein component (b) is selected from the group consisting of clozapine, olanzapine, risperidone and mixtures thereof or a pharmaceutically effective salt thereof.

20 22. A composition comprising:

(a) a pharmaceutically effective amount of one or more norepinephrine reuptake inhibitors or a pharmaceutically effective salt thereof; and

25 (b) a pharmaceutically effective amount of one or more neuroleptic agents or a pharmaceutically effective salt thereof for use as a medicament.